Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
|Articles|June 22, 2006
Pfizer To Phase Out Manufacturing at Groton
Author(s)Patricia Van Arnum
Pfizer, Inc. (New York, NY) will phase out manufacturing operations in Groton, Connecticut, eliminating roughly 300 jobs.
Advertisement
Pfizer, Inc. (New York, NY,
The move would allow the company to expand its research and developmentoperations in Groton near the 50-acre manufacturing site. Pfizer'sGroton and New London sites in Connecticut are the company's largestresearch sites, employing roughly 6000 people.
The move is part of Pfizer's company-wide restructuring effort,announced in 2005, under which Pfizer hopes to save $4 billion annuallyby 2008.
Pfizer plans to begin cutting its Groton manufacturing operations in2007. The facility makes active ingredients for several pharmaceuticalsand animal health products, and the company plans to transfer the manufacture of those products to other plants.
Advertisement
Related to this article
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Tavapadon Sets Development Benchmark for Parkinson's
2
KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech’s Weekly Roundup—September 25, 2026
5